Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


True North Therapeutics Inc.

Selectively inhibiting the complement system

This article was originally published in Start Up

Executive Summary

True North Therapeutics Inc. aims to develop a monoclonal antibody that acts as a complement inhibitor to shut down a key actor of the innate immune system known as the complement system. True North believes its preclinical candidate will work early in the complement pathway and be selective to C1s, thus shutting down only the “classic” complement pathway activated by antigen-antibody (immune) complexes.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts